Skip to main content
×
×
Home

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report

  • Asiel Yair Adan Sanchez (a1), Jessica J. Foster (a2), Carla M. Plymen (a3) and Sukhi Shergill (a4)
Abstract
Background

There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure that these treatments can be provided both safely and effectively.

Case presentation

A 36-year-old man with treatment-resistant schizophrenia and known hypertrophic cardiomyopathy (HCM) was admitted to a specialist unit for a trial of clozapine. His psychiatric illness was characterised by multimodal hallucinations and delusions combined with low mood and poor motivation. The diagnosis of HCM was made 3 years previously following a routine electrocardiogram (ECG), and he had remained asymptomatic throughout this time; there were concerns about the risk of initiating clozapine given his pre-existing cardiac condition. Baseline investigations were performed as per local guidelines prior to commencing clozapine; these were within normal limits other than a mildly raised troponin level of 54 ng/L (normal <16 ng/L), which was attributed to the HCM. In addition, baseline transthoracic echocardiography (TTE) was performed which showed no change in the structural heart disease in comparison with previous TTEs.

Clozapine was started at 12.5 mg daily and up-titrated to 150 mg twice daily over 14 days as per our institute's guidelines. The patient was monitored with regular testing of troponins, inflammatory markers and ECG. On day 18, the troponin level increased to 1371 ng/L. Creatine kinase and inflammatory markers remained stable. No changes in ECG or TTE were noted and the patient remained clinically asymptomatic. Cardiology opinion was sought and reported that the finding of an isolated elevated troponin was likely to reflect a ‘troponin leak’ in the context of increased cardiac muscle mass associated with HCM. In the absence of any clinical compromise, it was not felt to be of concern. Clozapine was continued with good effect on mental state. Troponin levels gradually reduced and the patient remained well.

Conclusions

While multiple cases of clozapine-induced cardiotoxicity have been reported in the literature, its implications for pre-existing structural disease are unclear. This case report suggests that clozapine can be safely introduced in pre-existing HCM, explores strategies for monitoring and highlights the importance of liaising with experienced cardiologists.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report
      Available formats
      ×
Copyright
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Corresponding author
Sukhi Shergill, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Denmark Hill, London SE5 9RS, UK. Email: sukhi.shergill@kcl.ac.uk
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Lieberman, JA, Saffermna, AZ, Pollack, S, Szymanski, S, Johns, C, Howard, A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744–52.
2 Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96.
3 Kane, JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996; 57 (suppl. 9): 3540.
4 Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7.
5 Alawami, M, Wasywich, C, Cicovic, A, Kenedi, C. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol 2014; 176: 315–20.
6 Berardis, DD, Serroni, N, Campanella, D, Olivieri, L, Ferri, F, Carano, A, et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Safety 2012; 7: 5562.
7 Layland, JJ, Liew, D, Prior, DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009; 190: 190–2.
8 Maron, BJ, Ommen, SR, Semsarian, C, Spirito, P, Olivotto, I, Martin, S, et al. Hypertrophic cardiomyopathy. JACC 2014; 64: 8399.
9 Haddock, G, McCarron, J, Tarrier, N, Faragher, EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med 1999; 29: 879–89.
10 Lovibond, PF, Lovidbond, SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scale (DASS) with the beck depression and anxiety inventories. Behav Res Ther 1955; 33: 335–43.
11 Elliot, PM, Anastasakis, A, Borger, MA, Borggrefe, M, Cecchi, F, Charron, P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35: 2733–79.
12 Wong, ET, Cobb, C, Umehara, MK, Wolff, GA, Haywood, LJ, Greenberg, T, et al. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol 1983; 79: 582–6.
13 Testani, M Jr. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55: 497–8.
14 Cohen, H, Loewenthal, J, Matar, MA, Kotler, M. Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report. Clin Neuropharmacol 2001; 24: 106–8.
15 Ewer, MS, Ewer, SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015; 12: 547–58.
16 Abdel-Wahab, BA, Metwally, ME. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-kb. Cardiovasc Toxicol 2015; 15: 355–65.
17 Abdel-Wahab, BA, Metwally, ME, El-khawanki, MM, Hashim, AM. Protective effect of captopril against clozapine-induced myocarditis in rats: role of oxidative stress, proinflammatory cytokines and DNA damage. Chem Biol Interact 2014; 216: 4352.
18 Cardinale, D, Colombo, A, Sandri, MT, Lamantia, G, Colombo, N, Civelli, M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474–81.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 4
Total number of PDF views: 24 *
Loading metrics...

Abstract views

Total abstract views: 91 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 17th July 2018. This data will be updated every 24 hours.

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report

  • Asiel Yair Adan Sanchez (a1), Jessica J. Foster (a2), Carla M. Plymen (a3) and Sukhi Shergill (a4)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *